Krystal Biotech (KRYS) Stock Forecast, Price Target & Predictions
KRYS Stock Forecast
Krystal Biotech stock forecast is as follows: an average price target of $191.00 (represents a -5.25% downside from KRYS’s last price of $201.58) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
KRYS Price Target
The average price target for Krystal Biotech (KRYS) is $191.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $220.00 to $133.00. This represents a potential -5.25% downside from KRYS's last price of $201.58.
KRYS Analyst Ratings
According to 8 Wall Street analysts, Krystal Biotech's rating consensus is 'Buy'. The analyst rating breakdown for KRYS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Krystal Biotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Dae Gon Ha | Stifel Nicolaus | $220.00 | $185.00 | 18.92% | 9.14% |
| Sep 02, 2024 | Alec Stranahan | Bank of America Securities | $205.00 | $195.12 | 5.06% | 1.70% |
| Aug 12, 2024 | Gavin Clark-Gartner | Evercore ISI | $206.00 | $182.17 | 13.08% | 2.19% |
| Apr 15, 2024 | Dae Gon Ha | Stifel Nicolaus | $204.00 | $169.75 | 20.18% | 1.20% |
| Nov 07, 2022 | Geulah Livshits | Chardan Capital | $133.00 | $78.05 | 70.40% | -34.02% |
| Aug 08, 2022 | Geulah Livshits | Chardan Capital | $130.00 | $82.40 | 57.77% | -35.51% |
The latest Krystal Biotech stock forecast, released on Sep 11, 2024 by Dae Gon Ha from Stifel Nicolaus, set a price target of $220.00, which represents a 18.92% increase from the stock price at the time of the forecast ($185.00), and a 9.14% increase from KRYS last price ($201.58).
Krystal Biotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 4 |
| Avg Price Target | $212.50 | $210.33 | $208.75 |
| Last Closing Price | $201.58 | $201.58 | $201.58 |
| Upside/Downside | 5.42% | 4.34% | 3.56% |
In the current month, the average price target of Krystal Biotech stock is $212.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 5.42% increase as opposed to Krystal Biotech's last price of $201.58. This month's average price target is up 1.03% compared to last quarter, and up 1.80% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Wedbush | Underperform | Underperform | Hold |
| Sep 11, 2024 | National Securities Corporation | Buy | Buy | Hold |
| Sep 11, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 05, 2024 | Citigroup | Buy | Neutral | Downgrade |
| Feb 27, 2024 | Guggenheim | Buy | Buy | Hold |
| Feb 27, 2024 | Citigroup | Buy | Buy | Hold |
| May 22, 2023 | Barclays | Buy | Buy | Hold |
| Feb 28, 2023 | Goldman Sachs | - | Buy | Upgrade |
Krystal Biotech's last stock rating was published by Wedbush on Sep 11, 2024. The company gave KRYS a "Underperform" rating, the same as its previous rate.
Krystal Biotech Financial Forecast
Krystal Biotech Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $8.56M | - | - | - |
| Avg Forecast | $205.66M | $212.01M | $181.38M | $159.46M | $146.53M | $155.47M | $135.04M | $116.13M | $131.55M | $131.51M | $115.14M | $101.55M | $95.89M | $84.17M | $65.27M | $47.37M | $28.55M | $6.29M | $142.86K | $663.41K | $290.29K |
| High Forecast | $233.83M | $241.06M | $206.23M | $181.31M | $166.61M | $176.77M | $153.54M | $132.04M | $149.57M | $149.53M | $130.92M | $115.46M | $109.02M | $86.10M | $74.21M | $53.86M | $44.93M | $7.15M | $162.43K | $796.10K | $348.34K |
| Low Forecast | $193.02M | $198.99M | $170.24M | $149.67M | $137.53M | $145.92M | $126.75M | $109.00M | $123.47M | $123.43M | $108.07M | $95.31M | $90.00M | $82.31M | $61.26M | $44.46M | $12.82M | $5.91M | $134.08K | $530.73K | $232.23K |
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.36% | - | - | - |
Krystal Biotech's average Quarter revenue forecast for Dec 23 based on 6 analysts is $28.55M, with a low forecast of $12.82M, and a high forecast of $44.93M. KRYS's average Quarter revenue forecast represents a 233.70% increase compared to the company's last Quarter revenue of $8.56M (Sep 23).
Krystal Biotech EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.99M | $-23.12M | $-3.98M | $-2.13M |
| Avg Forecast | $123.39M | $127.21M | $108.83M | $95.68M | $87.92M | $93.28M | $81.03M | $69.68M | $78.93M | $78.91M | $69.09M | $60.93M | $57.53M | $50.50M | $39.16M | $28.42M | $17.13M | $3.78M | $85.71K | $-5.11M | $-3.18M |
| High Forecast | $140.30M | $144.63M | $123.74M | $108.78M | $99.96M | $106.06M | $92.13M | $79.22M | $89.74M | $89.72M | $78.55M | $69.27M | $65.41M | $51.66M | $44.53M | $32.32M | $26.96M | $4.29M | $97.45K | $-4.09M | $-2.54M |
| Low Forecast | $115.81M | $119.39M | $102.14M | $89.80M | $82.52M | $87.55M | $76.05M | $65.40M | $74.08M | $74.06M | $64.84M | $57.19M | $54.00M | $49.39M | $36.76M | $26.68M | $7.69M | $3.54M | $80.45K | $-6.14M | $-3.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.88% | -269.71% | 0.78% | 0.67% |
undefined analysts predict KRYS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Krystal Biotech's previous annual EBITDA (undefined) of $NaN.
Krystal Biotech Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $80.75M | $-41.77M | $-4.11M | $-2.15M |
| Avg Forecast | $78.74M | $86.44M | $67.04M | $67.30M | $43.30M | $51.21M | $38.77M | $34.08M | $36.55M | $40.11M | $32.11M | $29.64M | $32.06M | $30.34M | $21.72M | $7.89M | $-9.14M | $-35.60M | $-42.63M | $-4.61M | $-3.02M |
| High Forecast | $92.76M | $101.84M | $78.98M | $79.28M | $51.01M | $60.33M | $45.68M | $40.15M | $43.06M | $47.25M | $37.82M | $34.91M | $37.77M | $40.19M | $25.59M | $9.30M | $-351.42K | $-32.76M | $-39.23M | $-3.69M | $-2.42M |
| Low Forecast | $72.45M | $79.54M | $61.69M | $61.92M | $39.84M | $47.12M | $35.68M | $31.36M | $33.63M | $36.91M | $29.54M | $27.27M | $29.50M | $20.88M | $19.99M | $7.26M | $-16.69M | $-41.94M | $-50.22M | $-5.53M | $-3.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.27% | 0.98% | 0.89% | 0.71% |
Krystal Biotech's average Quarter net income forecast for Dec 23 is $-9.14M, with a range of $-16.69M to $-351.42K. KRYS's average Quarter net income forecast represents a -111.32% decrease compared to the company's last Quarter net income of $80.75M (Sep 23).
Krystal Biotech SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $23.70M | $24.04M | $1.53M | $757.00K |
| Avg Forecast | $240.29M | $247.72M | $211.93M | $186.32M | $171.21M | $181.66M | $157.79M | $135.69M | $153.71M | $153.66M | $134.54M | $118.65M | $112.04M | $98.34M | $76.27M | $55.35M | $33.36M | $7.35M | $166.92K | $775.15K | $339.18K |
| High Forecast | $273.21M | $281.66M | $240.96M | $211.84M | $194.67M | $206.54M | $179.40M | $154.28M | $174.76M | $174.71M | $152.97M | $134.90M | $127.38M | $100.60M | $86.71M | $62.93M | $52.50M | $8.36M | $189.78K | $930.18K | $407.01K |
| Low Forecast | $225.53M | $232.51M | $198.91M | $174.88M | $160.70M | $170.50M | $148.10M | $127.36M | $144.27M | $144.22M | $126.27M | $111.36M | $105.15M | $96.18M | $71.58M | $51.95M | $14.97M | $6.90M | $156.66K | $620.12K | $271.34K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.22% | 143.99% | 1.97% | 2.23% |
Krystal Biotech's average Quarter SG&A projection for Dec 23 is $33.36M, based on 6 Wall Street analysts, with a range of $14.97M to $52.50M. The forecast indicates a 40.78% rise compared to KRYS last annual SG&A of $23.70M (Sep 23).
Krystal Biotech EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 20 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.88 | $-1.62 | $-0.29 | $-0.21 |
| Avg Forecast | $2.66 | $2.92 | $2.26 | $2.27 | $1.46 | $1.73 | $1.31 | $1.15 | $1.23 | $1.35 | $1.08 | $1.00 | $1.08 | $1.02 | $0.73 | $0.27 | $-0.31 | $-1.20 | $-1.44 | $-0.33 | $-0.67 |
| High Forecast | $3.13 | $3.44 | $2.66 | $2.68 | $1.72 | $2.04 | $1.54 | $1.35 | $1.45 | $1.59 | $1.28 | $1.18 | $1.27 | $1.36 | $0.86 | $0.31 | $-0.01 | $-1.11 | $-1.32 | $-0.31 | $-0.54 |
| Low Forecast | $2.44 | $2.68 | $2.08 | $2.09 | $1.34 | $1.59 | $1.20 | $1.06 | $1.13 | $1.25 | $1.00 | $0.92 | $1.00 | $0.70 | $0.67 | $0.24 | $-0.56 | $-1.42 | $-1.69 | $-0.36 | $-0.81 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.40% | 1.13% | 0.88% | 0.31% |
According to 6 Wall Street analysts, Krystal Biotech's projected average Quarter EPS for Dec 23 is $-0.31, with a low estimate of $-0.56 and a high estimate of $-0.01. This represents a -110.70% decrease compared to KRYS previous annual EPS of $2.88 (Sep 23).
Krystal Biotech Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RGNX | REGENXBIO | $12.84 | $38.00 | 195.95% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
| RYTM | Rhythm Pharmaceuticals | $49.62 | $38.33 | -22.75% | Buy |
KRYS Forecast FAQ
Is Krystal Biotech a good buy?
Yes, according to 8 Wall Street analysts, Krystal Biotech (KRYS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of KRYS's total ratings.
What is KRYS's price target?
Krystal Biotech (KRYS) average price target is $191 with a range of $133 to $220, implying a -5.25% from its last price of $201.58. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Krystal Biotech stock go up soon?
According to Wall Street analysts' prediction for KRYS stock, the company can go down by -5.25% (from the last price of $201.58 to the average price target of $191), up by 9.14% based on the highest stock price target, and down by -34.02% based on the lowest stock price target.
Can Krystal Biotech stock reach $300?
KRYS's average twelve months analyst stock price target of $191 does not support the claim that Krystal Biotech can reach $300 in the near future.
What is Krystal Biotech's current price target trend?
2 Wall Street analysts forecast a $212.5 price target for Krystal Biotech (KRYS) this month, up 5.42% from its last price of $201.58. Compared to the last 3 and 12 months, the average price target increased by 4.34% and increased by 3.56%, respectively.
What are Krystal Biotech's analysts' financial forecasts?
Krystal Biotech's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $553.18M (high $628.96M, low $519.2M), average EBITDA is $331.91M (high $377.38M, low $311.52M), average net income is $167.36M (high $197.17M, low $154M), average SG&A $646.35M (high $734.89M, low $606.65M), and average EPS is $5.65 (high $6.65, low $5.2). KRYS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $758.51M (high $862.42M, low $711.92M), average EBITDA is $455.11M (high $517.45M, low $427.15M), average net income is $299.52M (high $352.86M, low $275.6M), average SG&A $886.26M (high $1.01B, low $831.83M), and average EPS is $10.11 (high $11.91, low $9.3).
Did the KRYS's actual financial results beat the analysts' financial forecasts?
Based on Krystal Biotech's last annual report (Dec 2023), the company's revenue was $50.7M, beating the average analysts forecast of $34.99M by 44.91%. Apple's EBITDA was $-110M, missing the average prediction of $20.99M by -622.71%. The company's net income was $10.93M, missing the average estimation of $-87.368M by -112.51%. Apple's SG&A was $98.4M, beating the average forecast of $40.88M by 140.71%. Lastly, the company's EPS was $0.0004, missing the average prediction of $-2.948 by -100.01%. In terms of the last quarterly report (Sep 2023), Krystal Biotech's revenue was $8.56M, beating the average analysts' forecast of $6.29M by 35.97%. The company's EBITDA was $-25.993M, missing the average prediction of $3.78M by -788.47%. Krystal Biotech's net income was $80.75M, missing the average estimation of $-35.599M by -326.82%. The company's SG&A was $23.7M, beating the average forecast of $7.35M by 222.31%. Lastly, the company's EPS was $2.88, missing the average prediction of $-1.201 by -339.77%